Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Urothelial Carcinoma”

70 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 70 results

Early research (Phase 1)Study completedNCT00016237
What this trial is testing

Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment

Who this might be right for
Bladder CancerKidney CancerLung Cancer
EMD Serono
Testing effectiveness (Phase 2)Study completedNCT01687244
What this trial is testing

Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer

Who this might be right for
Superficial Bladder Cancer
FKD Therapies Oy 40
Testing effectiveness (Phase 2)Looking for participantsNCT07322263
What this trial is testing

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

Who this might be right for
Bladder CancerNon-Muscle Invasive Bladder Cancer (NMIBC)Urothelial Carcinoma+8 more
Michael A. O'Donnell 174
Testing effectiveness (Phase 2)Active Not RecruitingNCT04739800
What this trial is testing

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Who this might be right for
Fallopian Tube Mucinous AdenocarcinomaOvarian Seromucinous CarcinomaPlatinum-Refractory Fallopian Tube Carcinoma+47 more
National Cancer Institute (NCI) 120
Testing effectiveness (Phase 2)Looking for participantsNCT06364956
What this trial is testing

Clinical Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial Carcinoma

Who this might be right for
Bladder Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 36
Early research (Phase 1)Not Yet RecruitingNCT07725796
What this trial is testing

Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC

Who this might be right for
Bladder (Urothelial, Transitional Cell) CancerNMIBCUrothelial Carcinoma Bladder+5 more
UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd. 30
Testing effectiveness (Phase 2)Looking for participantsNCT07087860
What this trial is testing

Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers

Who this might be right for
Metastatic Bladder Urothelial CarcinomaMetastatic Renal Pelvis and Ureter Urothelial CarcinomaRefractory Bladder Urothelial Carcinoma+3 more
Mayo Clinic 70
Testing effectiveness (Phase 2)Active Not RecruitingNCT03179943
What this trial is testing

Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma

Who this might be right for
Urothelial Carcinoma
Fox Chase Cancer Center 21
Testing effectiveness (Phase 2)Study completedNCT02581982
What this trial is testing

Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer

Who this might be right for
Transitional Cell Carcinoma
Wake Forest University Health Sciences 27
Testing effectiveness (Phase 2)Looking for participantsNCT03945162
What this trial is testing

Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

Who this might be right for
Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
Theralase® Technologies Inc. 90
Early research (Phase 1)WithdrawnNCT05940844
What this trial is testing

Study of OB-002 in Patients With Refractory Metastatic Cancer

Who this might be right for
Metastatic CancerMetastatic Colorectal CancerMetastatic Pancreatic Cancer+3 more
Orion Biotechnology Polska Sp. z o.o.
Early research (Phase 1)Ended earlyNCT02925533
What this trial is testing

Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract

Who this might be right for
Bladder Cancer
Mark Pomerantz, MD 1
Large-scale testing (Phase 3)Ended earlyNCT01200992
What this trial is testing

Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer

Who this might be right for
Bladder NeoplasmNeoplasm Recurrence, LocalTransitional Cell, Carcinoma+2 more
Bioniche Life Sciences Inc. 84
Testing effectiveness (Phase 2)Study completedNCT00578526
What this trial is testing

SU011248 for Platinum-Refractory Urothelial Cancer Evaluation Trial

Who this might be right for
Urothelial CancerBladder CancerAdult
AHS Cancer Control Alberta 64
Testing effectiveness (Phase 2)Ended earlyNCT01732107
What this trial is testing

Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression

Who this might be right for
Bladder Cancer
Noah Hahn, M.D. 13
Testing effectiveness (Phase 2)Ended earlyNCT03287050
What this trial is testing

Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma

Who this might be right for
Urothelial Carcinoma
University of Michigan Rogel Cancer Center 6
Early research (Phase 1)Active Not RecruitingNCT04514484
What this trial is testing

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

Who this might be right for
Advanced Differentiated Thyroid Gland CarcinomaAdvanced Head and Neck CarcinomaAdvanced Hepatocellular Carcinoma+60 more
National Cancer Institute (NCI) 8
Testing effectiveness (Phase 2)Ended earlyNCT02901548
What this trial is testing

Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder

Who this might be right for
Carcinoma in Situ of BladderBladder Cancer
H. Lee Moffitt Cancer Center and Research Institute 17
Testing effectiveness (Phase 2)Ended earlyNCT01118351
What this trial is testing

Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer

Who this might be right for
Recurrent Bladder CancerTransitional Cell Carcinoma of the Bladder
Case Comprehensive Cancer Center 19
Early research (Phase 1)Active Not RecruitingNCT05843448
What this trial is testing

IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer

Who this might be right for
High Risk Non-Muscle Invasive Bladder Urothelial CarcinomaStage 0a Bladder Cancer AJCC v8Stage 0is Bladder Cancer AJCC v8+1 more
University of California, Davis 6
Next Page